FDA Grants Interchangeable Status to Celltrion’s YUFLYMA
Celltrion’s YUFLYMA® Secures Full FDA Interchangeability Status Across All Approved Forms and Strengths, Reinforcing Market Leadership and Commitment to Affordable Biologics Celltrion, Inc., a global biopharmaceutical company headquartered in South…
Grifols Gets FDA Nod for Phase 2 Trial of Eye Drops for Dry Eye Disease
Grifols Secures FDA Clearance to Advance Immunoglobulin Eye Drops into Phase 2 Trial for Dry Eye Disease Grifols, a global leader in the production of plasma-derived medicines and a prominent…
Analyzing the Economic and Commercial Drivers of Health in Small Island Developing States
Charting a Healthier Future: A Comprehensive Analysis of Economic and Commercial Determinants of Health in Small Island Developing States A newly released technical paper by the World Health Organization (WHO)…
Alnylam Releases 2024 Corporate Responsibility Report Highlighting ESG Progress
Alnylam Pharmaceuticals Unveils 2024 Corporate Responsibility Report, Showcasing Impact Across ESG Pillars Alnylam Pharmaceuticals, the industry leader in RNA interference (RNAi) therapeutics, has published its 2024 Corporate Responsibility Report, reaffirming…
BioNTech Strengthens UK Alliance to Enhance Regional R&D Initiatives
BioNTech Strengthens Partnership with UK Government to Significantly Expand Regional Research and Development Efforts BioNTech , a leading biotechnology firm recognized globally for its pioneering work in mRNA technology and…
Single Baby’s CRISPR Cure Sheds Light on Rare Disease Emergency
CRISPR Breakthrough in a Single Infant Sheds Light on the Urgent Crisis Facing Millions with Ultra-Rare Diseases A groundbreaking success story involving a custom-made CRISPR gene-editing therapy has given new…
Merck and imec Partner to Advance Next-Generation Microphysiological Systems Platform
Merck and imec Forge Strategic Alliance to Revolutionize Drug Discovery Through Advanced Microphysiological Systems Merck, a global leader in science and technology, and imec, a premier international hub for research…
Aetna Better Health of Illinois Invests $20.4 Million to Improve Statewide Health Outcomes
Aetna Better Health of Illinois Invests $20.4 Million to Strengthen Value-Based Care and Improve Health Equity Across the State Aetna Better Health® of Illinois, a Medicaid managed care plan and…
Roche Shares FDA Panel Update on Columvi Combo for Relapsed DLBCL
Roche Provides Update on FDA Advisory Committee Review of Columvi Combination Therapy for Relapsed or Refractory DLBCL Roche has shared an important regulatory update concerning its investigational treatment for a…
Novavax COVID Vaccine Gets Narrow FDA Nod as Makary Hints at Vaccine Approval Overhaul
FDA Grants Limited Approval to Novavax COVID-19 Vaccine Amid Signs of Upcoming Changes to Vaccine Approval Process The recent decision by the U.S. Food and Drug Administration (FDA) to grant…
Japan Approves Blenrep Combos for Relapsed/Refractory Multiple Myeloma
GSK Secures Japanese Approval for Blenrep Combinations in Relapsed/Refractory Multiple Myeloma Based on Robust Phase III Data In a major advancement for the treatment landscape of multiple myeloma, GSK plc…
Regeneron to Acquire 23andMe for $256M, Will Keep Consumer Genetics Business
Regeneron to Acquire Core Assets of 23andMe for $256 Million in Bankruptcy Auction, Pledges to Preserve Consumer Genetics Mission and Strengthen Human Health Research In a major development within the…